Open AccessCost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
Author(s) -
Marzieh Zargaran,
Fatemeh Soleymani,
Saman Ahmad Nasrollahi,
Meysam Seyedifar,
M.M. Ashrafian rahaghi
Publication year - 2021
Publication title -
research in pharmaceutical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.685
H-Index - 29
eISSN - 1735-9414
pISSN - 1735-5362
DOI - 10.4103/1735-5362.319576
Subject(s) - apremilast , psoriasis , medicine , plaque psoriasis , quality of life (healthcare) , dermatology , psoriatic arthritis , nursing
Plaque psoriasis is a chronic inflammatory disease with skin manifestations that affect the patients' quality of life negatively. The prevalence of psoriasis is approximately 2-3% worldwide and appears to be still on the increase. Due to the stigma problems, psoriasis has a significant effect on one's life that is often overlooked. The current study aimed to conduct the cost-utility evaluation and budget impact analysis of adding-on apremilast ahead of biologic therapy in the treatment of moderate to severe plaque psoriasis. The psoriatic patients who did not undergo the conventional systemic therapy were eligible to enter the defined sequences.